肾去神经术联合导管消融对阵发性房颤合并高血压患者房颤复发的影响:ERADICATE-AF随机临床试验
ERADICATE-AF多中心单盲随机试验纳入302例药物控制不佳高血压的阵发性房颤患者,比较肺静脉隔离联合肾去神经术与单纯肺静脉隔离。
要点
- 肾去神经术联合同步肺静脉隔离可显著降低阵发性房颤合并高血压患者12个月复发风险。
核心结论
- 在阵发性房颤合并高血压患者中,肾去神经术联合导管消融较单纯导管消融显著提高12个月无房颤/房扑/房速生存率。
- 解读结果时应考虑该试验缺乏假手术对照的肾去神经术操作。
研究设计与样本
- 多中心、单盲、随机临床试验,由研究者发起,在俄罗斯、波兰和德国的5个转诊中心开展。
- 2013年4月至2018年3月共纳入302例患者,随机分为单纯肺静脉隔离组(n=148)和肺静脉隔离联合肾去神经术组(n=154),随访至2019年3月结束。
- 纳入标准为至少使用1种降压药仍高血压、阵发性房颤且计划行导管消融的患者;283例(93.7%)完成试验。
主要发现
- 12个月无房颤/房扑/房速生存率:单纯肺静脉隔离组56.5%(84/148),联合肾去神经术组72.1%(111/154)。
- 30天内操作并发症:单纯组7例(4.7%),联合组7例(4.5%)。
关键数值与推荐
- 主要终点为12个月无房颤、房扑或房速发作。
- 次要终点包括30天内操作并发症及6个月和12个月血压控制。
- 5个预设次要终点中报告4个,其中3个组间存在差异。
临床怎么用
- 对于阵发性房颤合并高血压且计划行导管消融的患者,可考虑同期行肾去神经术以降低房颤复发并辅助降压。
- 联合术式未显著增加30天内操作并发症风险(4.5% vs 4.7%)。
- 需注意该试验未设假手术对照,结果解读应谨慎。
局限性
- 缺乏正式假手术对照的肾去神经术操作,可能影响结果解释。
- 试验仅在俄罗斯、波兰和德国的5个中心进行,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Renal denervation can reduce cardiac sympathetic activity that may result in an antiarrhythmic effect on atrial fibrillation. OBJECTIVE: To determine whether renal denervation when added to pulmonary vein isolation enhances long-term antiarrhythmic efficacy. DESIGN, SETTING, AND PARTICIPANTS: The Evaluate Renal Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial was an investigator-initiated, multicenter, single-blind, randomized clinical trial conducted at 5 referral centers for catheter ablation of atrial fibrillation in the Russian Federation, Poland, and Germany. A total of 302 patients with hypertension despite taking at least 1 antihypertensive medication, paroxysmal atrial fibrillation, and plans for ablation were enrolled from April 2013 to March 2018. Follow-up concluded in March 2019. INTERVENTIONS: Patients were randomized to either pulmonary vein isolation alone (n = 148) or pulmonary vein isolation plus renal denervation (n = 154). Complete pulmonary vein isolation to v an end point of elimination of all pulmonary vein potentials; renal denervation using an irrigated-tip ablation catheter delivering radiofrequency energy to discrete sites in a spiral pattern from distal to proximal in both renal arteries. MAIN OUTCOMES AND MEASURES: The primary end point was freedom from atrial fibrillation, atrial flutter, or atrial tachycardia at 12 months. Secondary end points included procedural complications within 30 days and blood pressure control at 6 and 12 months. RESULTS: Of the 302 randomized patients (median age, 60 years [interquartile range, 55-65 years]; 182 men [60.3%]), 283 (93.7%) completed the trial. All successfully underwent their assigned procedures. Freedom from atrial fibrillation, flutter, or tachycardia at 12 months was observed in 84 of 148 (56.5%) of those undergoing pulmonary vein isolation alone and in 111 of 154 (72.1%) of those undergoing pulmonary vein isolation plus renal denervation (hazard ratio, 0.57; 95% CI, 0.38 to 0.85; P = .006). Of 5 prespecified secondary end points, 4 are reported and 3 differed between groups. Mean systolic blood pressure from baseline to 12 months decreased from 151 mm Hg to 147 mm Hg in the isolation-only group and from 150 mm Hg to 135 mm Hg in the renal denervation group (between-group difference, -13 mm Hg; 95% CI, -15 to -11 mm Hg; P < .001). Procedural complications occurred in 7 patients (4.7%) in the isolation-only group and 7 (4.5%) of the renal denervation group. CONCLUSIONS AND RELEVANCE: Among patients with paroxysmal atrial fibrillation and hypertension, renal denervation added to catheter ablation, compared with catheter ablation alone, significantly increased the likelihood of freedom from atrial fibrillation at 12 months. The lack of a formal sham-control renal denervation procedure should be considered in interpreting the results of this trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01873352.
引用
- Steinberg JS, Shabanov V, Ponomarev D, et al. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA. 2020. PMID: 31961420. doi:10.1001/jama.2019.21187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。